Literature DB >> 14475000

Physiological effects and clinical evaluation of glycopyrrolate in peptic ulcer disease.

H C MOELLER.   

Abstract

Entities:  

Keywords:  PARASYMPATHOLYTICS/pharmacology; PEPTIC ULCER/therapy; STOMACH/pharmacology

Mesh:

Substances:

Year:  1962        PMID: 14475000     DOI: 10.1111/j.1749-6632.1962.tb45299.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  7 in total

1.  RATIONALE FOR THE USE OF ANTICHOLINERGIC AGENTS IN THE MANAGEMENT OF DUODENAL ULCER.

Authors:  K H SOERGEL; W J HOGAN
Journal:  Am J Dig Dis       Date:  1964-09

2.  Glycopyrrolate methobromide. 1. Effect on salivary secretion.

Authors:  G M Wyant; E Kao
Journal:  Can Anaesth Soc J       Date:  1974-03

3.  Some pitfalls in antisecretory drug trials. Subject selection, collection period, and daytime variation.

Authors:  J G Moore; E Englert
Journal:  Am J Dig Dis       Date:  1967-10

4.  A controlled trial of glycopyrronium and l-hyoscyamine in the long-term treatment of duodenal ulcer.

Authors:  M D Kaye; J Rhodes; P Beck; P M Sweetnam; G T Davies; K T Evans
Journal:  Gut       Date:  1970-07       Impact factor: 23.059

5.  Evaluation of the anticholinergic actions of glycopyrronium bromide.

Authors:  R K Mirakhur; J W Dundee; C J Jones
Journal:  Br J Clin Pharmacol       Date:  1978-01       Impact factor: 4.335

6.  The effect of glycopyrrolate (Robinul) on the lower oesophageal sphincter.

Authors:  J G Brock-Utne; J Rubin; S Welman; G E Dimopoulos; M G Moshal; J W Downing
Journal:  Can Anaesth Soc J       Date:  1978-03

7.  Gastric acid secretion in patients with duodenal ulcer treated for one year with anticholinergic drugs.

Authors:  M D Kaye; P Beck; J Rhodes; P M Sweetnam
Journal:  Gut       Date:  1969-10       Impact factor: 23.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.